KRYS · Krystal Biotech, Inc.
$311.50
-2.70% last session
End-of-day data · close of 2026-10-23
Market cap
$9B
Enterprise value
$8B
Trailing P/E
39.0
Forward P/E
34.8
Dividend yield
0.0%
Beta
0.50
Avg volume
0M
Employees
0K
Daily Change %
-2.70%
5 Days Change
1.12%
10 Days Change
-0.32%
30 Days Change
-6.33%
60 Days Change
-6.32%
Month to Day Change
-1.59%
Year to Day Change
29.85%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — KRYS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-15
Latest call per bank · past 12 months
Bank of America
Buy$400
+28.4% vs priceRBC Capital
Outperform$400
+28.4% vs priceCitigroup
Buy$386
+23.9% vs priceJefferies
Buy$371
+19.1% vs priceGoldman Sachs
Buy$327
+5.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | HC Wainwright & Co. | Reiterates | Buy | $361 |
| 2026-09-21 | Bank of America | Maintains | Buy | $392 → $400 |
| 2026-08-14 | RBC Capital | Initiates | Outperform | $0.00 → $400 |
| 2026-08-04 | Citigroup | Maintains | Buy | $378 → $386 |
| 2026-07-14 | Bank of America | Maintains | Buy | $364 → $396 |
| 2026-06-18 | TD Cowen | Maintains | Buy | $306 → $403 |
| 2026-06-16 | HC Wainwright & Co. | Maintains | Buy | $310 → $361 |
| 2026-06-01 | HC Wainwright & Co. | Reiterates | Buy | $310 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 38 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 8.1% below the 50-day MA ($338.84).
- bullish: Price vs 200-day MA: Trading 1.4% above the 200-day MA ($307.30).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.78) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($185.05) and high ($378.15).
KRYS Price Chart
Loading chart for KRYS…
Fundamentals
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.